A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Enoxaparin in Venous Thromboembolism, sponsored by Bayer. Completed at 676 sites in 53 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-09-15.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 26 in phase 3, and was the 10th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
Wolfson Medical Center · Sites in Israel
Ages 18–50 · Women only
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 29 · Phase 4 12
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,101 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 272 across the 61 interventional studies. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 61 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
39 studies in Venous Thromboembolism by Bayer: 1 open now, 2 under way, none of them phase 3. Of 35 finished, 6 (17%) have results posted.
Among the 39 studies in Venous Thromboembolism by Bayer, this one has the largest enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 10th registered.
Bayer’s Venous Thromboembolism studies by the year they started, since 2004.
8 of the studies testing rivaroxaban in Venous Thromboembolism that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05029063Phase 3Ottawa Hospital Research InstitutePrimary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | 2026-12 |
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, from their registry updates:
Among Bayer’s 39 in Venous Thromboembolism:
This tab as a report to print or save as PDF → With an account.
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.
The treatment period was followed by a follow-up period starting the day after the last intake of study medication, regardless of the actual duration of study drug administration and ended on Day 90 (+ 7 days). Participants who did not complete the treatment period also entered the follow-up period. It was also possible that participants did not enter the follow-up period, e.g. due to withdrawal of consent or termination of study participation.
Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients at risk of venous thromboembolic events being hospitalized for acute medical conditions as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Enoxaparin placebo
Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
Drug: Enoxaparin · Drug: Rivaroxaban placebo
Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
Time frame: Up to Day 35 + 6 days
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
Time frame: Up to Day 10 + 5 days
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).
Time frame: Up to Day 35 + 6 days
Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
Time frame: Up to Day 10 + 5 days
Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).
Time frame: Up to Day 10 + 5 days
Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90
Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90
Time frame: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events.
Time frame: Up to Day 35 + 6 days
Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events
Time frame: Up to Day 10 + 5 days
Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90
Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category.
Time frame: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
Time frame: Up to Day 35 + 6 days
Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
Time frame: Up to Day 10 + 5 days
Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days
All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths.
Time frame: Up to Day 90 + 7 days
Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)
Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin; or transfusion of \>= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding
Time frame: Up to Day 35 + 6 days
Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)
Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin or transfusion of \>=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding.
Time frame: Up to Day 10 + 5 days
First patient first visit date: 04 DEC 2007; last patient last visit date 24 NOV 2010. Primary completion date: 12 AUG 2010. Participants were aged ≥40 years, hospitalized for an acute medical illness, and at risk of Venous Thromboembolism (VTE) (with heart failure, cancer, ischemic stroke, infection or inflammation, or respiratory insufficiency)
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Started | 4050 | 4051 |
| Participants received treatment | 3997 | 4001 |
| Day 10 | 3454 | 3499 |
| Day 35 | 3033 | 3115 |
| Completed | 2958 | 3047 |
| Not completed | 1092 | 1004 |
| Withdrew: Adverse event | 438 | 385 |
| Withdrew: Clinical endpoint reached | 50 | 56 |
| Withdrew: Withdrawal by subject | 285 | 255 |
| Withdrew: Death | 76 | 59 |
| Withdrew: Physician decision | 8 | 9 |
| Withdrew: Lost to follow-up | 43 | 41 |
| Withdrew: Non-compliant with study medication | 88 | 89 |
| Withdrew: Patient convenience | 11 | 13 |
| Withdrew: Protocol violation | 90 | 92 |
| Withdrew: Technical problems | 3 | 5 |
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Started | 3583 | 3635 |
| Completed | 3038 | 3107 |
| Not completed | 545 | 528 |
| Withdrew: Adverse event | 46 | 40 |
| Withdrew: Clinical endpoint reached | 5 | 2 |
| Withdrew: Withdrawal by subject | 119 | 115 |
| Withdrew: Death | 132 | 133 |
| Withdrew: Physician decision | 7 | 13 |
| Withdrew: Lost to follow-up | 95 | 92 |
| Withdrew: Patient convenience | 136 | 121 |
| Withdrew: Protocol violation | 5 | 12 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days | 4.4 | 5.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days | 2.7 | 2.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days | 8.6 | 9.2 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population | 3.0 | 3.1 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related).
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days | 4.8 | 4.5 |
Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| symptomatic VTE (incl. VTE-related death)-Day 10 | 0.7 | 0.6 |
| symptomatic VTE (non fatal)-Day 10 | 0.5 | 0.3 |
| symptomatic VTE (incl. VTE-related death)-Day 35 | 1.0 | 1.4 |
| symptomatic VTE (non fatal)-Day 35 | 0.6 | 0.7 |
| symptomatic VTE (incl. VTE-related death)-Day 90 | 1.7 | 1.9 |
| symptomatic VTE (non fatal)-Day 90 | 0.7 | 0.9 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days | 9.4 | 7.8 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days | 4.5 | 3.9 |
Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Any event-Day 10 | 1.0 | 1.0 |
| Ischemic stroke-Day 10 | 0.3 | 0.3 |
| Acute MI-Day 10 | 0.5 | 0.4 |
| Death (cardiovascular)-Day 10 | 0.4 | 0.4 |
| Any event-Day 35 | 1.8 | 1.6 |
| Ischemic stroke-Day 35 | 0.5 | 0.5 |
| Acute MI-Day 35 | 0.6 | 0.5 |
| Death (cardiovascular)-Day 35 | 0.9 | 0.8 |
| Any event-Day 90 | 2.8 | 2.8 |
| Ischemic stroke-Day 90 | 0.8 | 1.1 |
| Acute MI-Day 90 | 0.9 | 0.7 |
| Death (cardiovascular)-Day 90 | 1.4 | 1.4 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Symptomatic non-fatal PE | 0.3 | 0.5 |
| Symptomatic DVT in lower extremity | 0.4 | 0.5 |
| Asymptomatic proximal DVT in lower extremity | 3.5 | 4.4 |
| VTE related death | 0.6 | 1.0 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Symptomatic non-fatal PE | 0.2 | 0.1 |
| Symptomatic DVT in lower extremity | 0.2 | 0.2 |
| Asymptomatic proximal DVT in lower extremity | 2.4 | 2.4 |
| VTE related death | 0.1 | 0.2 |
All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Any event | 6.7 | 6.2 |
| Death (cardiovascular) | 1.4 | 1.4 |
| Death (other) | 4.3 | 3.7 |
| VTE related death | 1.0 | 1.1 |
Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin; or transfusion of \>= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days) | 4.1 | 1.7 |
Major bleeding events were defined as events leading to \>=2 g/dL fall in hemoglobin or transfusion of \>=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days) | 2.8 | 1.2 |
Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | — | 1,034/3,997 (25.9%) | 2,297/3,997 (57.5%) |
| Enoxaparin | — | 976/4,001 (24.4%) | 2,291/4,001 (57.3%) |
| Event | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 109/3997 | 104/4001 |
| Cardiac failureCardiac disorders | 76/3997 | 76/4001 |
| PneumoniaInfections and infestations | 74/3997 | 76/4001 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 56/3997 | 40/4001 |
| Ischaemic strokeNervous system disorders | 30/3997 | 39/4001 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 35/3997 | 12/4001 |
| Cardiac failure congestiveCardiac disorders | 31/3997 | 31/4001 |
| Renal failure acuteRenal and urinary disorders | 31/3997 | 16/4001 |
| Acute myocardial infarctionCardiac disorders | 30/3997 | 28/4001 |
| SepsisInfections and infestations | 29/3997 | 14/4001 |
| Event | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin |
|---|---|---|
| ConstipationGastrointestinal disorders | 362/3997 | 346/4001 |
| DiarrhoeaGastrointestinal disorders | 214/3997 | 230/4001 |
| NauseaGastrointestinal disorders | 207/3997 | 226/4001 |
| HeadacheNervous system disorders | 205/3997 | 185/4001 |
| HypokalaemiaMetabolism and nutrition disorders | 191/3997 | 184/4001 |
| InsomniaPsychiatric disorders | 172/3997 | 185/4001 |
| VomitingGastrointestinal disorders | 170/3997 | 149/4001 |
| HypertensionVascular disorders | 154/3997 | 156/4001 |
| Urinary tract infectionInfections and infestations | 138/3997 | 142/4001 |
| Oedema peripheralGeneral disorders | 132/3997 | 115/4001 |
| Age, Continuous(years) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin | Total |
|---|---|---|---|
| Mean | 69.2 ± 11.9 | 69.2 ± 11.7 | 69.2 ± 11.8 |
| Age, Customized(participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin | Total |
|---|---|---|---|
| < 65 years | 1323 | 1363 | 2686 |
| 65 to < 75 years | 1144 | 1090 | 2234 |
| >= 75 years | 1530 | 1548 | 3078 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin | Total |
|---|---|---|---|
| Female | 1774 | 1898 | 3672 |
| Male | 2223 | 2103 | 4326 |
| Race(participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin | Total |
|---|---|---|---|
| White | 2749 | 2744 | 5493 |
| Black | 89 | 92 | 181 |
| Asian | 793 | 794 | 1587 |
| Native American | 12 | 12 | 24 |
| Hispanic | 69 | 70 | 139 |
| Uncodable | 106 | 112 | 218 |
| Unknown | 1 | 0 | 1 |
| Missing | 178 | 177 | 355 |
| Reason for hospitalization(participants) | Rivaroxaban (Xarelto, BAY59-7939) | Enoxaparin | Total |
|---|---|---|---|
| Heart failure (NYHA Class III or NYHA Class IV) | 1292 | 1301 | 2593 |
| Active cancer | 294 | 290 | 584 |
| Acute ischemic stroke | 691 | 692 | 1383 |
| Acute Infectious and Inflammatory Diseases | 1904 | 1876 | 3780 |
| Acute infectious disease | 1826 | 1801 | 3627 |
| Acute inflammatory or rheumatic disease | 150 | 149 | 299 |
| Acute respiratory insufficiency | 1085 | 1151 | 2236 |
Showing the first 100 of 676 sites across 53 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2007, a primary completion of Aug 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban